Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kayti Aviano
Observed name:
K. Aviano
Institution:
Pieris Pharmaceuticals (United States)
Observed institution:
Pieris Pharmaceuticals (United States)
ORCID:
0009-0006-1729-5599
Observed ORCID:
0009-0006-1729-5599
OpenAlex ID:
A5060068748
O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies
2020
·
Sarina Piha-Paul
, Johanna Bendell
, et al.
·
Oral Presentations
·
35
PDF
525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
2020
·
G. Ku
, J.C. Bendell
, et al.
·
Annals of Oncology
·
31
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2024
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
·
Clinical Cancer Research
·
23
PDF
P-53 A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma
2022
·
G. Ku
, S. Piha-Paul
, et al.
·
Annals of Oncology
·
7
Abstract CT154: Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma
2023
·
Geoffrey Ku
, Jeeyun Lee
, et al.
·
Cancer Research
·
3
Abstract CT017: Clinical and biomarker activity of PRS-343, a bispecific fusion protein targeting 4-1BB and HER2, from a phase 1 study in patients with advanced solid tumors (Study PRS-343-PCS_04_16)
2021
·
Sarina Piha-Paul
, Johanna C. Bendell
, et al.
·
Clinical Trials
·
3
Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma
2022
·
Sarina A. Piha-Paul
, Mukul Gupta
, et al.
·
Cancer Research
·
2
S1630 a Phase Iia Study to Evaluate the Safety, Pk and Pd of Repeated Administrations of the Hepcidin Antagonist Prs‐080 in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis
2019
·
L. Renders
, F. Dellana
, et al.
·
HemaSphere
·
1
Elarekibep, an inhaled Anticalin protein, targets IL-4Rα locally: first-in-human randomized phase 1 trials of a novel potential therapeutic class in asthma
2026
·
Ingmar B. Bruns
, Jason D. Lickliter
, et al.
·
Respiratory Research
Elarekibep, an inhaled Anticalin protein, targets IL-4Rα locally: first-in-human randomized phase 1 trials of a novel potential therapeutic class in asthma
2026
·
Ingmar B. Bruns
, Jason D. Lickliter
, et al.
·
Figshare
Supplementary Figure S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
Data from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
Supplementary Table S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
Supplementary Table S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
Supplementary Table S5 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
Supplementary Table S4 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
Supplementary Figure S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
Supplementary Table S3 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025
·
Sarina Piha-Paul
, Shane A. Olwill
, et al.
Show more works
View as search
Works count:
18
Citation count:
105
H-index:
4
I10-index:
3
Year
Topic
Type